维持性血透患者不同流感疫苗配方的比较效果
该队列研究基于美国肾脏数据系统,纳入≥65岁维持性血透患者,比较五种流感疫苗配方对流感样疾病、流感、流感相关住院、重症流感和全因死亡的风险。高剂量和细胞培养疫苗较标准剂量疫苗提供适度增加的保护,支持CDC推荐≥65岁成人使用增强型流感疫苗。
要点
- 高剂量疫苗较标准剂量疫苗对流感rVE 5.1%,流感相关住院rVE 5.5%,重症流感rVE 13.7%。
- 细胞培养疫苗较标准剂量疫苗对流感rVE 18.3%。
- 佐剂和重组疫苗估计不精确,需更多数据。
核心结论
- 高剂量和细胞培养疫苗较标准剂量疫苗在老年血透患者中提供适度增加的流感保护。
研究设计与样本
- 基于美国肾脏数据系统的主动对照队列研究,纳入≥65岁维持性血透患者,2011/2012至2019/2020流感季,共578232患者-季节。
主要发现
- 高剂量疫苗对比标准剂量疫苗:流感rVE 5.1%(95%CI -0.7%至10.5%),流感相关住院rVE 5.5%(95%CI -1.8%至12.3%),重症流感rVE 13.7%(95%CI -9.7%至32.1%)。
- 细胞培养疫苗对比标准剂量疫苗:流感rVE 18.3%(95%CI 2.2%至31.7%)。
- 佐剂或重组疫苗对比标准剂量疫苗的估计不精确。
临床怎么用
- 在≥65岁维持性血透患者中,可优先考虑高剂量或细胞培养流感疫苗以适度增加保护。
局限性
- 部分估计不精确,尤其是佐剂和重组疫苗;观察性设计可能存在残余混杂,但定量偏倚分析未提示。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In patients with kidney failure, enhanced influenza vaccine formulations may provide modestly increased protection versus standard-dose vaccines. This cohort study compared the risk of influenza-like illness, influenza, influenza-related hospitalization, severe influenza, and all-cause mortality by vaccine formulation. Findings support new Centers for Disease Control and Prevention guidelines recommending enhanced influenza vaccine formulations in adults ≥65 years, regardless of kidney failure. BACKGROUND: Influenza vaccination is recommended to prevent influenza in patients with kidney failure. It remains unclear whether newer, enhanced vaccine formulations are more effective than standard-dose, egg-based, inactivated influenza vaccine (standard-dose vaccine) in patients undergoing maintenance hemodialysis. We sought to compare the effectiveness of five influenza vaccine formulations among patients undergoing hemodialysis. METHODS: Using the United States Renal Data System database, we performed an active comparator cohort study among adults ≥65 years with kidney failure undergoing hemodialysis (2011/2012-2019/2020 influenza seasons) who received a standard-dose, high-dose, cell culture-based, adjuvanted, or recombinant influenza vaccine within a given season. We compared the risk of influenza-like illness, influenza, influenza-related hospitalization, severe influenza, and all-cause mortality during the influenza season by vaccine formulation. Season-specific risk differences and relative vaccine effectiveness (rVE) were estimated using propensity score-weighted Kaplan-Meier functions, accounting for the competing risk of death (for nonmortality outcomes). We combined the season-specific estimates via a random effects meta-analysis. RESULTS: 578,232 influenza patient-seasons included standard-dose vaccine ( n =372,907), high-dose vaccine ( n =192,880), cell culture-based vaccine ( n =8177), adjuvanted vaccine ( n =3308), or recombinant vaccine ( n =960). Season-specific and meta-analytic estimates were consistent with a modest protective effect of high-dose vaccine versus standard-dose vaccine for influenza (meta-analytic rVE 5.1%; 95% confidence interval [CI], -0.7% to 10.5%), influenza-related hospitalization (meta-analytic rVE 5.5%; CI, -1.8% to 12.3%), and severe influenza (meta-analytic rVE 13.7%; CI, -9.7% to 32.1%), but not influenza-like illness or mortality. Patterns were similar for cell culture-based vaccine versus standard-dose vaccine ( e.g ., meta-analytic rVE for influenza, 18.3%; CI, 2.2% to 31.7%). Estimates for adjuvanted or recombinant versus standard-dose vaccines were imprecise. Quantitative bias analyses did not indicate residual confounding, although some estimates were imprecise. CONCLUSIONS: Among older adults undergoing hemodialysis, high-dose vaccine and cell culture-based vaccine provided modestly increased protection versus standard-dose vaccine.
引用
- Davis JW, Layton JB, Sahrmann JM, et al. Comparative Effectiveness of Different Influenza Vaccine Formulations among Patients Undergoing Maintenance Hemodialysis. J Am Soc Nephrol. 2026. PMID: 41973506. doi:10.1681/ASN.0000001099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。